

# Harald Hampel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7609799/publications.pdf>

Version: 2024-02-01

471  
papers

68,835  
citations

1238

110  
h-index

851

244  
g-index

550  
all docs

550  
docs citations

550  
times ranked

49984  
citing authors

#	ARTICLE	IF	CITATIONS
1	State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 159-177.	0.8	33
2	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	9.0	97
3	Toward noninvasive brain stimulation 2.0 in Alzheimer's disease. <i>Ageing Research Reviews</i> , 2022, 75, 101555.	10.9	37
4	Evaluation of major national dementia policies and health-care system preparedness for early medical action and implementation. <i>Alzheimer's and Dementia</i> , 2022, 18, 1993-2002.	0.8	7
5	New insights into the genetic etiology of Alzheimer's disease and related dementias. <i>Nature Genetics</i> , 2022, 54, 412-436.	21.4	700
6	Association of $\beta$ -Amyloid and Basal Forebrain With Cortical Thickness and Cognition in Alzheimer and Lewy Body Disease Spectra. <i>Neurology</i> , 2022, 98, .	1.1	10
7	$\beta$ -synuclein as an emerging pathophysiological biomarker of Alzheimer's disease. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 411-425.	3.1	4
8	Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. <i>Neuropharmacology</i> , 2021, 185, 108081.	4.1	27
9	The $\beta$ -Secretase BACE1 in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2021, 89, 745-756.	1.3	336
10	Aptamer prediction of brain amyloid- $\beta$ status in cognitively normal individuals at risk for Alzheimer's disease. <i>PLoS ONE</i> , 2021, 16, e0243902.	2.5	5
11	MiRNA-15b and miRNA-125b are associated with regional A $\beta$ -PET and FDG-PET uptake in cognitively normal individuals with subjective memory complaints. <i>Translational Psychiatry</i> , 2021, 11, 78.	4.8	13
12	Progress regarding the context-of-use of tau as biomarker of Alzheimer's disease and other neurodegenerative diseases. <i>Expert Review of Proteomics</i> , 2021, 18, 27-48.	3.0	8
13	Plasma $\beta$ -secretase1 concentrations correlate with basal forebrain atrophy and neurodegeneration in cognitively healthy individuals at risk for AD. <i>Alzheimer's and Dementia</i> , 2021, 17, 629-640.	0.8	10
14	Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel. <i>Alzheimer's and Dementia</i> , 2021, 17, 1528-1553.	0.8	64
15	EEG measures for clinical research in major vascular cognitive impairment: recommendations by an expert panel. <i>Neurobiology of Aging</i> , 2021, 103, 78-97.	3.1	9
16	Developing the ATX(N) classification for use across the Alzheimer disease continuum. <i>Nature Reviews Neurology</i> , 2021, 17, 580-589.	10.1	144
17	Ultrasensitive techniques and protein misfolding amplification assays for biomarker-guided reconceptualization of Alzheimer's and other neurodegenerative diseases. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 949-967.	2.8	4
18	Omics sciences for systems biology in Alzheimer's disease: State-of-the-art of the evidence. <i>Ageing Research Reviews</i> , 2021, 69, 101346.	10.9	74

#	ARTICLE	IF	CITATIONS
19	The Amyloid- $\beta$ Pathway in Alzheimer's Disease. <i>Molecular Psychiatry</i> , 2021, 26, 5481-5503.	7.9	478
20	Association of plasma A $\beta$ 40/A $\beta$ 42 ratio and brain A $\beta$ accumulation: testing a whole-brain PLS-VIP approach in individuals at risk of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2021, 107, 57-69.	3.1	5
21	Locus coeruleus assessment by MRI: A comparison of three different approaches. <i>Journal of the Neurological Sciences</i> , 2021, 429, 118309.	0.6	0
22	Biological Mechanism-based Neurology and Psychiatry: a BACE1/2 and Downstream Pathway Model. <i>Current Neuropharmacology</i> , 2021, 19, .	2.9	1
23	Partial Volume Correction Increases the Sensitivity of 18F-Florbetapir-Positron Emission Tomography for the Detection of Early Stage Amyloidosis. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 748198.	3.4	3
24	Education and brain amyloid load act on temporal lobe function in individual with subjective memory complaint: An EEG-fMRI study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
25	Reduction of recruitment costs in preclinical AD trials: validation of automatic pre-screening algorithm for brain amyloidosis. <i>Statistical Methods in Medical Research</i> , 2020, 29, 151-164.	1.5	30
26	What electrophysiology tells us about Alzheimer's disease: a window into the synchronization and connectivity of brain neurons. <i>Neurobiology of Aging</i> , 2020, 85, 58-73.	3.1	150
27	Association of brain network dynamics with plasma biomarkers in subjective memory complainers. <i>Neurobiology of Aging</i> , 2020, 88, 83-90.	3.1	4
28	Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. <i>Neurology</i> , 2020, 94, e30-e41.	1.1	20
29	Randomized controlled trial on the efficacy of a multilevel non-pharmacologic intervention in older adults with subjective memory decline: design and baseline findings of the E.Mu.N.I. study. <i>Aging Clinical and Experimental Research</i> , 2020, 32, 817-826.	2.9	6
30	RATIONALE FOR EARLY DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT (MCI) SUPPORTED BY EMERGING DIGITAL TECHNOLOGIES. <i>Journal of prevention of Alzheimer's disease, The</i> , 2020, 7, 1-7.	2.7	37
31	$\beta$ -Secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 130.	6.2	16
32	The role of synaptic biomarkers in the spectrum of neurodegenerative diseases. <i>Expert Review of Proteomics</i> , 2020, 17, 543-559.	3.0	16
33	Abnormalities of resting-state EEG in patients with prodromal and overt dementia with Lewy bodies: Relation to clinical symptoms. <i>Clinical Neurophysiology</i> , 2020, 131, 2716-2731.	1.5	11
34	Association of plasma YKL-40 with brain amyloid- $\beta$ levels, memory performance, and sex in subjective memory complainers. <i>Neurobiology of Aging</i> , 2020, 96, 22-32.	3.1	18
35	Resting-state posterior alpha rhythms are abnormal in subjective memory complaint seniors with preclinical Alzheimer's neuropathology and high education level: the INSIGHT-preAD study. <i>Neurobiology of Aging</i> , 2020, 90, 43-59.	3.1	30
36	microRNA-Based Biomarkers in Alzheimer's Disease (AD). <i>Frontiers in Neuroscience</i> , 2020, 14, 585432.	2.8	57

#	ARTICLE	IF	CITATIONS
37	Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 147.	6.2	23
38	Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases. <i>Molecular Neurobiology</i> , 2020, 57, 4667-4691.	4.0	33
39	Biomarkers for Alzheimer's Disease (AD) and the Application of Precision Medicine. <i>Journal of Personalized Medicine</i> , 2020, 10, 138.	2.5	15
40	THE SARS-COV-2 PANDEMIC AND THE BRAVE NEW DIGITAL WORLD OF ENVIRONMENTAL ENRICHMENT TO PREVENT BRAIN AGING AND COGNITIVE DECLINE. <i>Journal of prevention of Alzheimer's disease</i> , The, 2020, 7, 1-5.	2.7	7
41	Association of plasma YKL40 with brain amyloidosis, memory performance, and sex in subjective memory complainers. <i>Alzheimer's and Dementia</i> , 2020, 16, e041753.	0.8	0
42	Aging and sex impact plasma NFL and t-Tau trajectories in individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e041792.	0.8	2
43	Cortical microstructural changes and amyloid beta burden in cognitively normal subjective memory complainers. <i>Alzheimer's and Dementia</i> , 2020, 16, e046014.	0.8	0
44	Sex differences in cortical microstructural changes in asymptomatic individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e046105.	0.8	0
45	Accuracy of MRI Classification Algorithms in a Tertiary Memory Center Clinical Routine Cohort. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 1157-1166.	2.6	19
46	Exercise benefits on Alzheimer's disease: State-of-the-science. <i>Ageing Research Reviews</i> , 2020, 62, 101108.	10.9	153
47	Abnormal cortical neural synchronization mechanisms in quiet wakefulness are related to motor deficits, cognitive symptoms, and visual hallucinations in Parkinson's disease patients: an electroencephalographic study. <i>Neurobiology of Aging</i> , 2020, 91, 88-111.	3.1	24
48	In vivo staging of regional amyloid deposition predicts functional conversion in the preclinical and prodromal phases of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 93, 98-108.	3.1	21
49	The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 421-441.	3.1	42
50	A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX273) Phase 2a clinical study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12013.	3.7	31
51	A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. <i>Frontiers in Immunology</i> , 2020, 11, 456.	4.8	201
52	EARLY DETECTION OF MILD COGNITIVE IMPAIRMENT (MCI) IN PRIMARY CARE. <i>Journal of prevention of Alzheimer's disease</i> , The, 2020, 7, 1-6.	2.7	58
53	EARLY DETECTION OF MILD COGNITIVE IMPAIRMENT (MCI) IN AN AT-HOME SETTING. <i>Journal of prevention of Alzheimer's disease</i> , The, 2020, 7, 1-8.	2.7	38
54	Successful aging: insights from proteome analyses of healthy centenarians. <i>Ageing</i> , 2020, 12, 3502-3515.	3.1	31

#	ARTICLE	IF	CITATIONS
55	REVISITING THE CHOLINERGIC HYPOTHESIS IN ALZHEIMER'S DISEASE: EMERGING EVIDENCE FROM TRANSLATIONAL AND CLINICAL RESEARCH. <i>Journal of prevention of Alzheimer's disease</i> , The, 2019, 6, 1-14.	2.7	135
56	Time for the systems-level integration of aging: Resilience enhancing strategies to prevent Alzheimer's disease. <i>Progress in Neurobiology</i> , 2019, 181, 101662.	5.7	38
57	Brain A $\beta$ load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD. <i>Alzheimer's and Dementia</i> , 2019, 15, 1274-1285.	0.8	25
58	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. <i>Lancet Neurology</i> , The, 2019, 18, 1034-1044.	10.2	85
59	Biomarker-guided clustering of Alzheimer's disease clinical syndromes. <i>Neurobiology of Aging</i> , 2019, 83, 42-53.	3.1	48
60	Abnormalities of functional cortical source connectivity of resting-state electroencephalographic alpha rhythms are similar in patients with mild cognitive impairment due to Alzheimer's and Lewy body diseases. <i>Neurobiology of Aging</i> , 2019, 77, 112-127.	3.1	33
61	Lithium as a Treatment for Alzheimer's Disease: The Systems Pharmacology Perspective. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 615-629.	2.6	44
62	Blood-based diagnostics of Alzheimer's disease. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 613-621.	3.1	11
63	A frontline defense against neurodegenerative diseases: the development of early disease detection methods. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 559-563.	3.1	12
64	The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development. <i>Expert Review of Proteomics</i> , 2019, 16, 593-600.	3.0	41
65	Plasma amyloid A $\beta$ 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 764-775.	0.8	122
66	Differential default mode network trajectories in asymptomatic individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 940-950.	0.8	43
67	COMMENTARY: DEVELOPMENT OF THE BLOOD-BASED ALZHEIMER'S DISEASE LIQUID BIOPSY. <i>Journal of prevention of Alzheimer's disease</i> , The, 2019, 6, 1-3.	2.7	3
68	Biomarker-Drug and Liquid Biopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for Alzheimer's Precision Medicine and Pharmacology. <i>Frontiers in Pharmacology</i> , 2019, 10, 310.	3.5	35
69	The Alzheimer Precision Medicine Initiative. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 1-24.	2.6	75
70	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A $\beta$ , tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	21.4	1,962
71	Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia. <i>Alzheimer's and Dementia</i> , 2019, 15, 465-476.	0.8	232
72	Relationship between Basal Forebrain Resting-State Functional Connectivity and Brain Amyloid A $\beta$ Deposition in Cognitively Intact Older Adults with Subjective Memory Complaints. <i>Radiology</i> , 2019, 290, 167-176.	7.3	30

#	ARTICLE	IF	CITATIONS
73	Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease. <i>Dialogues in Clinical Neuroscience</i> , 2019, 21, 177-191.	3.7	17
74	Cognitive and neuroimaging features and brain $\beta$ -amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study. <i>Lancet Neurology</i> , The, 2018, 17, 335-346.	10.2	161
75	Magnetic resonance imaging-based hippocampus volume for prediction of dementia in mild cognitive impairment: Why does the measurement method matter so little?. <i>Alzheimer's and Dementia</i> , 2018, 14, 976-978.	0.8	4
76	Precision pharmacology for Alzheimer's disease. <i>Pharmacological Research</i> , 2018, 130, 331-365.	7.1	79
77	Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: $A\beta_{42}$ , total $\tau$ , phosphorylated $\tau$ , NFL, neurogranin, and YKL40. <i>Alzheimer's and Dementia</i> , 2018, 14, 492-501.	0.8	91
78	Prevalence of the apolipoprotein E $\epsilon$ 4 allele in amyloid $\beta$ positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924.	0.8	58
79	Revolution of Alzheimer Precision Neurology. <i>Passageway of Systems Biology and Neurophysiology. Journal of Alzheimer's Disease</i> , 2018, 64, S47-S105.	2.6	122
80	Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment. <i>Biological Psychiatry</i> , 2018, 83, 447-455.	1.3	83
81	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 244-328.	2.6	215
82	No association of cortical amyloid load and EEG connectivity in older people with subjective memory complaints. <i>NeuroImage: Clinical</i> , 2018, 17, 435-443.	2.7	19
83	Association of Cerebral Amyloid- $\beta$ Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	11.0	133
84	Evaluation of amyloid status in a cohort of elderly individuals with memory complaints: validation of the method of quantification and determination of positivity thresholds. <i>Annals of Nuclear Medicine</i> , 2018, 32, 75-86.	2.2	45
85	P3-218: NOVEL ALZHEIMER'S DISEASE BIOMARKER-GUIDED DIAGNOSTIC WORKFLOW USING THE ADDED VALUE OF SIX COMBINED CEREBROSPINAL FLUID CANDIDATES: $A\beta_{42}$ , TOTAL $\tau$ , PHOSPHORYLATED $\tau$ , NFL, NEUROGRANIN, AND YKL40. <i>Alzheimer's and Dementia</i> , 2018, 14, P1154.	0.8	1
86	P4-072: INCREASED PLASMA BACE1 CONCENTRATIONS IN WOMEN WITH SUBJECTIVE MEMORY COMPLAINTS: CORRELATION WITH PLASMA NFL. <i>Alzheimer's and Dementia</i> , 2018, 14, P1461.	0.8	0
87	P1-627: AMYLOID BURDEN IMPACTS EVERYDAY FUNCTIONING INDEPENDENT OF COGNITION AND AWARENESS IN SUBJECTIVE COGNITIVE DECLINE: FINDINGS FROM THE INSIGHT PRE-AD COHORT. <i>Alzheimer's and Dementia</i> , 2018, 14, P581.	0.8	0
88	P3-411: CLINICAL SIGNIFICANCE OF IN-VIVO STAGING OF REGIONAL AMYLOID DEPOSITION IN SUBJECTIVE MEMORY COMPLAINERS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1262.	0.8	0
89	P2-237: ASSOCIATION OF CSF ALPHA-SYNUCLEIN AND TAU CONCENTRATIONS WITH AMYLOID MEAN CORTICAL STANDARD UPTAKE VALUE RATIOS IN PRECLINICAL SUBJECTIVE MEMORY COMPLAINERS STRATIFIED BY ALZHEIMER'S DISEASE BIOMARKERS. <i>Alzheimer's and Dementia</i> , 2018, 14, P762.	0.8	0
90	P3-248: STRATIFICATION OF INDIVIDUALS FOR PET AMYLOID POSITIVITY AND ALZHEIMER'S DISEASE RISK USING POLYGENIC RISK SCORE ANALYSIS: NEW OPPORTUNITIES FOR CLINICAL TRIAL DESIGN. <i>Alzheimer's and Dementia</i> , 2018, 14, P1168.	0.8	0

#	ARTICLE	IF	CITATIONS
91	P4â€027: EVIDENCE FOR COGNITIVE COMPENSATION IN EARLY AMYLOIDOSIS IN HIGHâ€PERFORMING HEALTHY ELDERLY AT RISK FOR ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1443.	0.8	0
92	TURNING POINT TOWARDS BLOOD BIOMARKER-GUIDED TARGETED THERAPY FOR PRECISION MEDICINE IN ALZHEIMERâ€™S DISEASE. journal of prevention of Alzheimer's disease, The, 2018, 5, 1-5.	2.7	5
93	O4â€07â€04: INCREASED RESILIENCE TO ALZHEIMER'S DISEASE PATHOPHYSIOLOGY IN MEN WITH SUBJECTIVE MEMORY COMPLAINTS COMPARED TO WOMEN. Alzheimer's and Dementia, 2018, 14, P1419.	0.8	0
94	O3â€09â€02: CORRELATION AND LONGITUDINAL DYNAMICS OF PLASMA NFL AND TAU CONCENTRATIONS IN AMYLOIDâ€PET NEGATIVE INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS. Alzheimer's and Dementia, 2018, 14, P1036.	0.8	0
95	P4â€098: ASSOCIATION BETWEEN COGNITIVE RESERVE AND WHITE MATTER MICROSTRUCTURAL INTEGRITY IN OLDER ADULTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2018, 14, P1474.	0.8	0
96	P2â€397: REDUCED BASAL FOREBRAIN FUNCTIONAL CONNECTIVITY IN WOMEN WITH SUBJECTIVE MEMORY COMPLAINTS COMPARED TO MEN. Alzheimer's and Dementia, 2018, 14, P855.	0.8	0
97	P2â€246: INCREASED LONGITUDINAL DYNAMICS OF PLASMA YKLâ€40 CONCENTRATIONS IN AMYLOIDâ€PET POSITIVE INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS. Alzheimer's and Dementia, 2018, 14, P767.	0.8	0
98	P2â€249: CORRELATIONS AND ALTERED LONGITUDINAL DYNAMICS OF PLASMA BACE1 AND NFL CONCENTRATIONS IN INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS. Alzheimer's and Dementia, 2018, 14, P768.	0.8	0
99	Current state of Alzheimerâ€™s fluid biomarkers. Acta Neuropathologica, 2018, 136, 821-853.	7.7	370
100	Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nature Reviews Neurology, 2018, 14, 639-652.	10.1	434
101	P2â€355: CORRELATION OF FUNCTIONAL MRI CONNECTOMES WITH PATHOPHYSIOLOGICAL ALZHEIMER'S PLASMA BIOMARKERS AND RISK FACTORS IN SUBJECTIVE MEMORY COMPLAINERS. Alzheimer's and Dementia, 2018, 14, P824.	0.8	0
102	P1â€431: APOEâ€DEPENDENT LONGITUDINAL CHANGES IN DEFAULT MODE NETWORK FUNCTIONAL CONNECTIVITY IN SUBJECTIVE MEMORY COMPLAINERS. Alzheimer's and Dementia, 2018, 14, P474.	0.8	1
103	Basal Forebrain Volume, but Not Hippocampal Volume, Is a Predictor of Global Cognitive Decline in Patients With Alzheimer's Disease Treated With Cholinesterase Inhibitors. Frontiers in Neurology, 2018, 9, 642.	2.4	32
104	The cholinergic system in the pathophysiology and treatment of Alzheimerâ€™s disease. Brain, 2018, 141, 1917-1933.	7.6	1,008
105	Effect of Alzheimer's disease risk and protective factors on cognitive trajectories in subjective memory complainers: An INSIGHTâ€preAD study. Alzheimer's and Dementia, 2018, 14, 1126-1136.	0.8	20
106	Association of cerebrospinal fluid Î±â€synuclein with total and phosphoâ€tau<sub>181</sub> protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers. Alzheimer's and Dementia, 2018, 14, 1623-1631.	0.8	45
107	Reply: Optimal use of cholinergic drugs in Alzheimerâ€™s disease. Brain, 2018, 141, e69.	7.6	0
108	Sex differences in Alzheimer disease â€” the gateway to precision medicine. Nature Reviews Neurology, 2018, 14, 457-469.	10.1	573



#	ARTICLE	IF	CITATIONS
109	Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer's disease in cognitively normal older adults with subjective memory complaints. <i>Alzheimer's and Dementia</i> , 2018, 14, 1204-1215.	0.8	79
110	Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 67.	3.4	29
111	Aptamers as biomarkers for neurological disorders. Proof of concept in transgenic mice. <i>PLoS ONE</i> , 2018, 13, e0190212.	2.5	8
112	Precision medicine and drug development in Alzheimer's disease: the importance of sexual dimorphism and patient stratification. <i>Frontiers in Neuroendocrinology</i> , 2018, 50, 31-51.	5.2	46
113	Systems Biology Methods for Alzheimer's Disease Research Toward Molecular Signatures, Subtypes, and Stages and Precision Medicine: Application in Cohort Studies and Trials. <i>Methods in Molecular Biology</i> , 2018, 1750, 31-66.	0.9	36
114	Blood-Based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis Within the Dimensional Spectrum of Neurodegenerative Diseases. <i>Methods in Molecular Biology</i> , 2018, 1750, 139-155.	0.9	12
115	Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 47-57.	2.8	65
116	The European DTI Study on Dementia – A multicenter DTI and MRI study on Alzheimer's disease and Mild Cognitive Impairment. <i>NeuroImage</i> , 2017, 144, 305-308.	4.2	33
117	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 543-555.	2.6	10
118	Free and Cued Selective Reminding Test – accuracy for the differential diagnosis of Alzheimer's and neurodegenerative diseases: A large-scale biomarker-characterized monocenter cohort study (ClinAD). <i>Alzheimer's and Dementia</i> , 2017, 13, 913-923.	0.8	75
119	Non-Pharmacologic Interventions for Older Adults with Subjective Cognitive Decline: Systematic Review, Meta-Analysis, and Preliminary Recommendations. <i>Neuropsychology Review</i> , 2017, 27, 245-257.	4.9	97
120	Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases. <i>Expert Review of Proteomics</i> , 2017, 14, 285-299.	3.0	78
121	Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept. <i>Alzheimer's and Dementia</i> , 2017, 13, 454-467.	0.8	58
122	Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 993-1003.	0.8	39
123	A Precision Medicine Initiative for Alzheimer's disease: the road ahead to biomarker-guided integrative disease modeling. <i>Climacteric</i> , 2017, 20, 107-118.	2.4	112
124	Evolving Relevance of Neuroproteomics in Alzheimer's Disease. <i>Methods in Molecular Biology</i> , 2017, 1598, 101-115.	0.9	14
125	Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease. <i>Neurochemistry International</i> , 2017, 108, 355-360.	3.8	46
126	Disrupted white matter structural networks in healthy older adult APOE $\epsilon$ 4 carriers – An international multicenter DTI study. <i>Neuroscience</i> , 2017, 357, 119-133.	2.3	31



#	ARTICLE	IF	CITATIONS
127	Amyloidosis and neurodegeneration result in distinct structural connectivity patterns in mild cognitive impairment. <i>Neurobiology of Aging</i> , 2017, 55, 177-189.	3.1	20
128	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 56, 33-40.	3.1	27
129	Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 1327-1334.	2.6	35
130	Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 11706.	3.3	79
131	Rare coding variants in PLGG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017, 49, 1373-1384.	21.4	783
132	Revolution of Resting-State Functional Neuroimaging Genetics in Alzheimer's Disease. <i>Trends in Neurosciences</i> , 2017, 40, 469-480.	8.6	34
133	Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. <i>Alzheimer's and Dementia</i> , 2017, 13, 45-58.	0.8	227
134	Implementation of subjective cognitive decline criteria in research studies. <i>Alzheimer's and Dementia</i> , 2017, 13, 296-311.	0.8	375
135	A common challenge in older adults: Classification, overlap, and therapy of depression and dementia. <i>Alzheimer's and Dementia</i> , 2017, 13, 59-71.	0.8	112
136	Cerebrospinal Fluid Stanniocalcin-1 as a Biomarker for Alzheimer's Disease and Other Neurodegenerative Disorders. <i>NeuroMolecular Medicine</i> , 2017, 19, 154-160.	3.4	18
137	[ICAP152]: ASSOCIATION OF CORTICAL AMYLOID LOAD WITH RESTING-STATE EEG FUNCTIONAL CONNECTIVITY IN SUBJECTIVE MEMORY COMPLAINERS FROM THE INSIGHT-PRE AD STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P114.	0.8	0
138	[P1388]: DIFFERENT STRUCTURAL CONNECTIVITY PATTERNS IN MILD COGNITIVE IMPAIRMENT STRATIFIED BY AMYLOID AND NEURODEGENERATION BIOMARKERS. <i>Alzheimer's and Dementia</i> , 2017, 13, P414.	0.8	0
139	[P1441]: ASSOCIATION OF CORTICAL AMYLOID LOAD WITH RESTING-STATE EEG FUNCTIONAL CONNECTIVITY IN SUBJECTIVE MEMORY COMPLAINERS FROM THE INSIGHT-PRE AD STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P451.	0.8	0
140	Alzheimer's Disease Diagnosis Relies on a Twofold Clinical-Biological Algorithm: Three Memory Clinic Case Reports. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 577-583.	2.6	2
141	Fully Automatic MRI-Based Hippocampus Volumetry Using FSL-FIRST: Intra-Scanner Test-Retest Stability, Inter-Field Strength Variability, and Performance as Enrichment Biomarker for Clinical Trials Using Prodromal Target Populations at Risk for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 151-164.	2.6	7
142	Preclinical effects of APOE $\epsilon$ 4 on cerebrospinal fluid A $\beta$ 42 concentrations. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 87.	6.2	22
143	Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 101.	6.2	43
144	Cortical amyloid accumulation is associated with alterations of structural integrity in older people with subjective memory complaints. <i>Neurobiology of Aging</i> , 2017, 57, 143-152.	3.1	18

#	ARTICLE	IF	CITATIONS
145	Low Cognitive Awareness, but Not Complaint, is a Good Marker of Preclinical Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 59, 753-762.	2.6	36
146	A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology, 2016, 87, 539-547.	1.1	1,216
147	Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 3, 27-34.	2.4	44
148	Biomarker-guided classification scheme of neurodegenerative diseases. Journal of Sport and Health Science, 2016, 5, 383-387.	6.5	22
149	Shared genetic contribution to ischemic stroke and Alzheimer's disease. Annals of Neurology, 2016, 79, 739-747.	5.3	56
150	Performance of Hippocampus Volumetry with FSL-FIRST for Prediction of Alzheimer's Disease Dementia in at Risk Subjects with Amnesic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2016, 51, 867-873.	2.6	19
151	Combination of Structural MRI and ÂFDG-PET of the Brain Improves Diagnostic Accuracy in Newly Manifested Cognitive Impairment in Geriatric Inpatients. Journal of Alzheimer's Disease, 2016, 54, 1319-1331.	2.6	9
152	The rising global tide of cognitive impairment. Nature Reviews Neurology, 2016, 12, 131-132.	10.1	40
153	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimer's and Dementia, 2016, 12, 292-323.	0.8	1,318
154	The phenotypical core of Alzheimer's diseaseâ€related and nonrelated variants of the corticobasal syndrome: A systematic clinical, neuropsychological, imaging, and biomarker study. Alzheimer's and Dementia, 2016, 12, 786-795.	0.8	28
155	Effects of rivastigmine on visual attention in subjects with amnesic mild cognitive impairment: A serial functional MRI activation pilot-study. Psychiatry Research - Neuroimaging, 2016, 249, 84-90.	1.8	10
156	Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease. Neuropharmacology, 2016, 108, 128-135.	4.1	23
157	Application of Systems Theory in Longitudinal Studies on the Origin and Progression of Alzheimer's Disease. Methods in Molecular Biology, 2016, 1303, 49-67.	0.9	30
158	Mechanical stress related to brain atrophy in Alzheimer's disease. , 2016, 12, 11-20.		20
159	A novel Alzheimer disease locus located near the gene encoding tau protein. Molecular Psychiatry, 2016, 21, 108-117.	7.9	260
160	REGISTRIES AND COHORTS TO ACCELERATE EARLY PHASE ALZHEIMER'S TRIALS. A REPORT FROM THE E.U./U.S. CLINICAL TRIALS IN ALZHEIMER'S DISEASE TASK FORCE. journal of prevention of Alzheimer's disease, The, 2016, 3, 1-7.	2.7	36
161	Lithium as a Treatment for Alzheimer's Disease: A Systematic Review and ÂMeta-Analysis. Journal of Alzheimer's Disease, 2015, 48, 403-410.	2.6	138
162	Prediction of Alzheimer's Disease Dementia: Data from the GuidAge Prevention Trial. Journal of Alzheimer's Disease, 2015, 48, 793-804.	2.6	28

#	ARTICLE	IF	CITATIONS
163	Fully Automated Atlas-Based Hippocampus Volumetry for Clinical Routine: Validation in Subjects with Mild Cognitive Impairment from the ADNI Cohort. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 199-209.	2.6	25
164	Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S171-S191.	2.6	34
165	Biomarkers in Sporadic and Familial Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 291-317.	2.6	75
166	Fully Automated Atlas-Based Hippocampal Volumetry for Detection of Alzheimer's Disease in a Memory Clinic Setting. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 183-193.	2.6	29
167	The Latent Dementia Phenotype $\hat{\tau}$ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 547-560.	2.6	23
168	Predicting Progression from Cognitive Impairment to Alzheimer's Disease with the Disease State Index. <i>Current Alzheimer Research</i> , 2015, 12, 69-79.	1.4	22
169	Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. <i>Alzheimer's and Dementia</i> , 2015, 11, 549-560.	0.8	205
170	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. <i>Brain</i> , 2015, 138, 1327-1338.	7.6	284
171	The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity. <i>Alzheimer's and Dementia</i> , 2015, 11, 111-125.	0.8	162
172	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. <i>Brain</i> , 2015, 138, 2701-2715.	7.6	109
173	DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences" part 1: general aspects and paradigmatic discussion of depressive disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 5-18.	3.2	23
174	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1924.	7.4	1,166
175	Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease. <i>Nature Genetics</i> , 2015, 47, 445-447.	21.4	283
176	CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study. <i>Alzheimer's and Dementia</i> , 2015, 11, 1306-1315.	0.8	104
177	Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 83-105.	2.8	64
178	Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 58-69.	0.8	352
179	DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences" part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive-compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 87-106.	3.2	26
180	MRI-based imaging of Alzheimer's disease. , 2015, , 199-213.		0

#	ARTICLE	IF	CITATIONS
181	COGNITIVE REHABILITATION IN ALZHEIMER'S DISEASE – A CONCEPTUAL AND METHODOLOGICAL REVIEW. Journal of prevention of Alzheimer's disease, The, 2015, 2, 1-11.	2.7	8
182	Memory Concerns, Memory Performance and Risk of Dementia in Patients with Mild Cognitive Impairment. PLoS ONE, 2014, 9, e100812.	2.5	41
183	S3-01-02: SCREENING FOR AD: WHY AND HOW?. , 2014, 10, P200-P200.		0
184	Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease. JAMA Psychiatry, 2014, 71, 1183.	11.0	85
185	Increased Plasma TACE Activity in Subjects with Mild Cognitive Impairment and Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 41, 877-886.	2.6	26
186	The future of blood-based biomarkers for Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 115-131.	0.8	250
187	Biomarkers in Amyloid- $\beta$ Immunotherapy Trials in Alzheimer's Disease. Neuropsychopharmacology, 2014, 39, 189-201.	5.4	66
188	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurology, The, 2014, 13, 614-629.	10.2	2,657
189	Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments. Journal of Neurology, 2014, 261, 1234-1243.	3.6	30
190	The $\epsilon$ 4 genotype of apolipoprotein E and white matter integrity in Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 401-404.	0.8	25
191	Subregional Basal Forebrain Atrophy in Alzheimer's Disease: A Multicenter Study. Journal of Alzheimer's Disease, 2014, 40, 687-700.	2.6	173
192	CSF A $\beta$ 1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease. , 2014, 10, 381-392.		64
193	Standardization of MRI and Amyloid Imaging. , 2014, , 131-156.		2
194	Fractional Anisotropy Changes in Alzheimer's Disease Depend on the Underlying Fiber Tract Architecture: A Multiparametric DTI Study using Joint Independent Component Analysis. Journal of Alzheimer's Disease, 2014, 41, 69-83.	2.6	71
195	The cerebrospinal fluid "Alzheimer profile": Easily said, but what does it mean?. Alzheimer's and Dementia, 2014, 10, 713.	0.8	249
196	Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020. Biochemical Pharmacology, 2014, 88, 426-449.	4.4	105
197	CSF biomarkers for Alzheimer's pathology and the effect size of APOE $\epsilon$ 4. Molecular Psychiatry, 2014, 19, 148-149.	7.9	30
198	P2-192: ADVANCED DIFFUSION WEIGHTING IMAGING (DWI) TRACTOGRAPHY OF THE LIMBIC SYSTEM: NOVEL BIOMARKERS OF NEURODEGENERATIVE CHANGES DURING PROGRESSION/CONVERSION FROM COGNITIVE NORMALITY TO AD DEMENTIA. , 2014, 10, P541-P542.		1

#	ARTICLE	IF	CITATIONS
199	IC-P-067: ADVANCED DIFFUSION WEIGHTING IMAGING (DWI) TRACTOGRAPHY OF THE LIMBIC SYSTEM: NOVEL BIOMARKERS OF NEURODEGENERATIVE CHANGES DURING PROGRESSION/CONVERSION FROM COGNITIVE NORMALITY TO AD DEMENTIA. , 2014, 10, P37-P37.		0
200	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2014, 9, e94661.	2.5	155
201	THE ROAD AHEAD TO CURE ALZHEIMER'S DISEASE: DEVELOPMENT OF BIOLOGICAL MARKERS AND NEUROIMAGING METHODS FOR PREVENTION TRIALS ACROSS ALL STAGES AND TARGET POPULATIONS. journal of prevention of Alzheimer's disease, The, 2014, 1, 1-22.	2.7	48
202	E.U./U.S. CTAD TASK FORCE ON ALZHEIMER'S TRIAL POPULATIONS. journal of prevention of Alzheimer's disease, The, 2014, 1, 1-7.	2.7	4
203	Neural adaptation to thin and fat bodies in the fusiform body area and middle occipital gyrus: An fMRI adaptation study. Human Brain Mapping, 2013, 34, 3233-3246.	3.6	34
204	Blood and plasma-based proteomic biomarker research in Alzheimer's disease. Progress in Neurobiology, 2013, 101-102, 1-17.	5.7	115
205	Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement. Journal of Nutrition, Health and Aging, 2013, 17, 54-63.	3.3	28
206	Increased 3-Hydroxykynurenine serum concentrations differentiate Alzheimer's disease patients from controls. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 345-352.	3.2	103
207	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	21.4	3,741
208	Alzheimer disease: From biomarkers to diagnosis. Revue Neurologique, 2013, 169, 744-751.	1.5	22
209	Have we learnt all we need to know from genetic studies - is genetics over in Alzheimer's disease?. Alzheimer's Research and Therapy, 2013, 5, 11.	6.2	4
210	Variant of <i>TREM2</i> Associated with the Risk of Alzheimer's Disease. New England Journal of Medicine, 2013, 368, 107-116.	27.0	2,085
211	Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment. Neurobiology of Aging, 2013, 34, 2003-2013.	3.1	86
212	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.8	344
213	Biological and methodical challenges of blood-based proteomics in the field of neurological research. Progress in Neurobiology, 2013, 101-102, 18-34.	5.7	43
214	Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease. Nature Reviews Drug Discovery, 2013, 12, 324-324.	46.4	63
215	Relevance of Magnetic Resonance Imaging for Early Detection and Diagnosis of Alzheimer Disease. Medical Clinics of North America, 2013, 97, 399-424.	2.5	151
216	The Association Between APOE $\epsilon$ 4 and Alzheimer-type Dementia Among Memory Clinic Patients is Confined to those with a Higher Education. The DESCRIPA Study. Journal of Alzheimer's Disease, 2013, 35, 241-246.	2.6	7

#	ARTICLE	IF	CITATIONS
217	Single-Domain Amnesic Mild Cognitive Impairment Identified by Cluster Analysis Predicts Alzheimer's Disease in the European Prospective DESCRIPA Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2013, 36, 1-19.	1.5	41
218	Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. <i>Psychological Medicine</i> , 2013, 43, 911-920.	4.5	93
219	A New Sandwich Immunoassay for Detection of the $\beta$ -Secretase Cleaved, Soluble Amyloid- $\beta$ 2 Protein Precursor in Cerebrospinal Fluid and Serum. <i>Journal of Alzheimer's Disease</i> , 2013, 37, 667-678.	2.6	9
220	APOE-Dependent Phenotypes in Subjects with Mild Cognitive Impairment Converting to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 37, 389-401.	2.6	13
221	Diffusion Tensor Imaging to Determine Effects of Antidementia Treatment on Cerebral Structural Connectivity in Alzheimer's Disease. <i>Current Pharmaceutical Design</i> , 2013, 19, 6416-6425.	1.9	7
222	Robust Automated Detection of Microstructural White Matter Degeneration in Alzheimer's Disease Using Machine Learning Classification of Multicenter DTI Data. <i>PLoS ONE</i> , 2013, 8, e64925.	2.5	89
223	Imaging Epigenetics in Alzheimer's Disease. <i>Current Pharmaceutical Design</i> , 2013, 19, 6393-6415.	1.9	33
224	Diagnostik und Therapie demenzieller Syndrome (ICD-10 F0). , 2013, , 1-24.		0
225	Stage-Dependent Agreement between Cerebrospinal Fluid Proteins and FDG-PET Findings in Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2012, 9, 241-247.	1.4	16
226	Human Anti-prion Antibodies Block Prion Peptide Fibril Formation and Neurotoxicity. <i>Journal of Biological Chemistry</i> , 2012, 287, 12858-12866.	3.4	24
227	The Role of Variation at $\beta$ 2PP, PSEN1, PSEN2, and MAPT in Late Onset Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 377-387.	2.6	53
228	Diagnostic Tools: Fluid Biomarkers for Alzheimer's Disease. <i>Advances in Biological Psychiatry</i> , 2012, , 71-79.	0.2	0
229	Amyloid- $\beta$ 2 and Cognition in Aging and Alzheimer's Disease: Molecular and Neurophysiological Mechanisms. <i>Journal of Alzheimer's Disease</i> , 2012, 33, S79-S86.	2.6	44
230	Patterns of Autobiographical Memory in Bipolar Disorder Examined by Psychometric and Functional Neuroimaging Methods. <i>Journal of Nervous and Mental Disease</i> , 2012, 200, 296-304.	1.0	14
231	MRI- and PET-Based Imaging Markers for the Diagnosis of Alzheimer's Disease. <i>Advances in Biological Psychiatry</i> , 2012, , 80-114.	0.2	0
232	Anatomical MRI and DTI in the Diagnosis of Alzheimer's Disease: A European Multicenter Study. <i>Journal of Alzheimer's Disease</i> , 2012, 31, S33-S47.	2.6	86
233	Validation of AclarusDx, a Blood-Based Transcriptomic Signature for the Diagnosis of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 32, 169-181.	2.6	54
234	Current insights into the pathophysiology of Alzheimer's disease: selecting targets for early therapeutic intervention. <i>International Psychogeriatrics</i> , 2012, 24, S10-S17.	1.0	24



#	ARTICLE	IF	CITATIONS
235	From inherited to sporadic ADâ€”crossing the biomarker bridge. <i>Nature Reviews Neurology</i> , 2012, 8, 598-600.	10.1	36
236	Interhemispheric hypoconnectivity in schizophrenia: Fiber integrity and volume differences of the corpus callosum in patients and unaffected relatives. <i>NeuroImage</i> , 2012, 59, 926-934.	4.2	102
237	Development of biomarkers to chart all Alzheimer's disease stages: TheÂroyal road to cutting the therapeutic Gordian Knot. <i>Alzheimer's and Dementia</i> , 2012, 8, 312-336.	0.8	112
238	Association of microstructural white matter abnormalities with cognitive dysfunction in geriatric patients with major depression. <i>Psychiatry Research - Neuroimaging</i> , 2012, 203, 194-200.	1.8	36
239	Diagnostic power of default mode network resting state fMRI in the detection of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 466-478.	3.1	236
240	Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. <i>Neurobiology of Aging</i> , 2012, 33, 1203-1214.e2.	3.1	346
241	Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 1599-1608.	3.1	52
242	Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. <i>Neurobiology of Aging</i> , 2012, 33, 2272-2281.	3.1	75
243	Cognitive and behavioural effects of physical exercise in psychiatric patients. <i>Progress in Neurobiology</i> , 2012, 96, 46-68.	5.7	147
244	Recommendations to standardize preanalytical confounding factors in Alzheimerâ€™s and Parkinsonâ€™s disease cerebrospinal fluid biomarkers: an update. <i>Biomarkers in Medicine</i> , 2012, 6, 419-430.	1.4	280
245	Corticalâ€”basal ganglia imbalance in schizophrenia patients and unaffected first-degree relatives. <i>Schizophrenia Research</i> , 2012, 138, 120-127.	2.0	40
246	Association between white matter fiber integrity and subclinical psychotic symptoms in schizophrenia patients and unaffected relatives. <i>Schizophrenia Research</i> , 2012, 140, 129-135.	2.0	56
247	Amyloid-Î² Oligomers in Cerebrospinal Fluid are Associated with Cognitive Decline in Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 29, 171-176.	2.6	95
248	Using Support Vector Machines with Multiple Indices of Diffusion for Automated Classification of Mild Cognitive Impairment. <i>PLoS ONE</i> , 2012, 7, e32441.	2.5	80
249	Reduced Hippocampal Volume in Healthy Young ApoE4 Carriers: An MRI Study. <i>PLoS ONE</i> , 2012, 7, e48895.	2.5	168
250	Perspectives for Multimodal Neurochemical and Imaging Biomarkers in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 33, S329-S347.	2.6	21
251	Subjective memory complaints in community dwelling healthy older people: the influence of brain and psychopathology. <i>International Journal of Geriatric Psychiatry</i> , 2012, 27, 836-843.	2.7	37
252	Treatment Options for Tauopathies. <i>Current Treatment Options in Neurology</i> , 2012, 14, 126-136.	1.8	35

#	ARTICLE	IF	CITATIONS
253	Are biomarkers harmful to recruitment and retention in Alzheimer's disease clinical trials? An international perspective. <i>Journal of Nutrition, Health and Aging</i> , 2012, 16, 346-348.	3.3	10
254	Alzheimer's disease therapeutic trials: EU/US task force report on recruitment, retention, and methodology. <i>Journal of Nutrition, Health and Aging</i> , 2012, 16, 339-345.	3.3	38
255	Longitudinal changes of fractional anisotropy in Alzheimer's disease patients treated with galantamine: a 12-month randomized, placebo-controlled, double-blinded study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 341-350.	3.2	30
256	Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. <i>Journal of Neural Transmission</i> , 2012, 119, 39-52.	2.8	68
257	Metabolite Profiling of Alzheimer's Disease Cerebrospinal Fluid. <i>PLoS ONE</i> , 2012, 7, e31501.	2.5	143
258	White Matter Differences between Healthy Young ApoE4 Carriers and Non-Carriers Identified with Tractography and Support Vector Machines. <i>PLoS ONE</i> , 2012, 7, e36024.	2.5	19
259	Sexual Dimorphism in Healthy Aging and Mild Cognitive Impairment: A DTI Study. <i>PLoS ONE</i> , 2012, 7, e37021.	2.5	26
260	Long-Term Observation of a Multicomponent Cognitive Intervention in Mild Cognitive Impairment. <i>Journal of Clinical Psychiatry</i> , 2012, 73, e1492-e1498.	2.2	48
261	Diagnostik und Therapie demenzieller Syndrome (ICD-10 F0). , 2012, , 1-20.		0
262	Antihypertensive Therapy Is Associated with Reduced Rate of Conversion to Alzheimer's Disease in Midregional Proatrial Natriuretic Peptide Stratified Subjects with Mild Cognitive Impairment. <i>Biological Psychiatry</i> , 2011, 70, 145-151.	1.3	24
263	Blood-Based Protein Biomarkers for Diagnosis and Classification of Neurodegenerative Diseases. <i>Molecular Diagnosis and Therapy</i> , 2011, 15, 83-102.	3.8	25
264	Increased CSF-BACE1 Activity Associated with Decreased Hippocampus Volume in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 25, 373-381.	2.6	50
265	Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. <i>Trends in Neurosciences</i> , 2011, 34, 430-442.	8.6	309
266	Biomarkers for Alzheimer's disease therapeutic trials. <i>Progress in Neurobiology</i> , 2011, 95, 579-593.	5.7	119
267	Biomarker-based dissection of neurodegenerative diseases. <i>Progress in Neurobiology</i> , 2011, 95, 520-534.	5.7	82
268	Development of Alzheimer-disease neuroimaging-biomarkers using mouse models with amyloid-precursor protein-transgene expression. <i>Progress in Neurobiology</i> , 2011, 95, 547-556.	5.7	30
269	Discovery and development of integrative biological markers for schizophrenia. <i>Progress in Neurobiology</i> , 2011, 95, 686-702.	5.7	28
270	Functional magnetic resonance imaging as a dynamic candidate biomarker for Alzheimer's disease. <i>Progress in Neurobiology</i> , 2011, 95, 557-569.	5.7	53

#	ARTICLE	IF	CITATIONS
271	Recent developments of functional magnetic resonance imaging research for drug development in Alzheimer's disease. Progress in Neurobiology, 2011, 95, 570-578.	5.7	22
272	Staging Alzheimer's disease progression with multimodality neuroimaging. Progress in Neurobiology, 2011, 95, 535-546.	5.7	68
273	Neurodegenerative disease biomarkers: Guideposts for disease prevention through early diagnosis and intervention. Progress in Neurobiology, 2011, 95, 491-495.	5.7	40
274	Perspectives of worldwide translational biomarker research in neurodegenerative diseases. Progress in Neurobiology, 2011, 95, 496-497.	5.7	4
275	Biomarkers for major depression and its delineation from neurodegenerative disorders. Progress in Neurobiology, 2011, 95, 703-717.	5.7	39
276	Prevention trials in Alzheimer's disease: An EU-US task force report. Progress in Neurobiology, 2011, 95, 594-600.	5.7	62
277	Biomarkers in clinical trials for neurodegenerative diseases: Regulatory perspectives and requirements. Progress in Neurobiology, 2011, 95, 498-500.	5.7	29
278	The role of genetics for biomarker development in neurodegeneration. Progress in Neurobiology, 2011, 95, 501-504.	5.7	24
279	The future of Alzheimer's disease: The next 10 years. Progress in Neurobiology, 2011, 95, 718-728.	5.7	190
280	Ethical considerations of biomarker use in neurodegenerative diseasesâ€”A case study of Alzheimer's disease. Progress in Neurobiology, 2011, 95, 517-519.	5.7	27
281	Impact of employment status and work-related factors on risk of completed suicide. Psychiatry Research, 2011, 190, 265-270.	3.3	109
282	Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 474.	0.8	176
283	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's and Dementia, 2011, 7, 386.	0.8	354
284	CALHM1 P86L Polymorphism Modulates CSF A $\beta$ Levels in Cognitively Healthy Individuals at Risk for Alzheimer's Disease. Molecular Medicine, 2011, 17, 974-979.	4.4	26
285	Multiple Indices of Diffusion Identifies White Matter Damage in Mild Cognitive Impairment and Alzheimer's Disease. PLoS ONE, 2011, 6, e21745.	2.5	108
286	Effects of a Newly Developed Cognitive Intervention in Amnesic Mild Cognitive Impairment and mild Alzheimer's disease: A Pilot Study. Journal of Alzheimer's Disease, 2011, 25, 679-694.	2.6	121
287	Effects of a 6-Month Cognitive Intervention Program on Brain Metabolism in Amnesic Mild Cognitive Impairment and Mild Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 25, 695-706.	2.6	30
288	Using Diffusion Tensor Imaging and Mixed-Effects Models to Investigate Primary and Secondary White Matter Degeneration in Alzheimer's Disease and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2011, 26, 667-682.	2.6	33

#	ARTICLE	IF	CITATIONS
289	Effects of a 6-Month Cognitive Intervention on Brain Metabolism in Patients with Amnesic MCI and Mild Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 337-348.	2.6	45
290	Common capacity-limited neural mechanisms of selective attention and spatial working memory encoding. <i>European Journal of Neuroscience</i> , 2011, 34, 827-838.	2.6	31
291	Do Instrumental Activities of Daily Living Predict Dementia at 1- and 2-Year Follow-Up? Findings from the Development of Screening Guidelines and Diagnostic Criteria for Predementia Alzheimer's Disease Study. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 2273-2281.	2.6	59
292	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. <i>Nature Genetics</i> , 2011, 43, 429-435.	21.4	1,708
293	Multicenter stability of diffusion tensor imaging measures: A European clinical and physical phantom study. <i>Psychiatry Research - Neuroimaging</i> , 2011, 194, 363-371.	1.8	98
294	Revised criteria for Alzheimer's disease: what are the lessons for clinicians?. <i>Lancet Neurology</i> , The, 2011, 10, 598-601.	10.2	30
295	Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2011, 6, 69.	10.8	74
296	The cholinergic system in mild cognitive impairment and Alzheimer's disease: An in vivo MRI and DTI study. <i>Human Brain Mapping</i> , 2011, 32, 1349-1362.	3.6	136
297	Atrophy outcomes in multicentre clinical trials on Alzheimer's disease: Effect of different processing and analysis approaches on sample sizes. <i>World Journal of Biological Psychiatry</i> , 2011, 12, 109-113.	2.6	8
298	Regional Differences in Effects of $\epsilon$ -APOE $\epsilon$ 4 on Cognitive Impairment in Non-Demented Subjects. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 32, 135-142.	1.5	18
299	Amyloid $\text{A}\beta^2$ and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 367-374.	2.3	62
300	Left Anterior Temporal Lobe Sustains Naming in Alzheimers Dementia and Mild Cognitive Impairment. <i>Current Alzheimer Research</i> , 2011, 8, 893-901.	1.4	27
301	Different Effects of Mirtazapine and Venlafaxine on Brain Activation. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 448-457.	2.2	52
302	Prediction of Alzheimer's Disease Using Midregional Proadrenomedullin and Midregional Proatrial Natriuretic Peptide. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 556-563.	2.2	25
303	Longitudinal Changes in Fiber Tract Integrity in Healthy Aging and Mild Cognitive Impairment: A DTI Follow-Up Study. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 507-522.	2.6	157
304	Diagnostic Utility of Novel MRI-Based Biomarkers for Alzheimer's Disease: Diffusion Tensor Imaging and Deformation-Based Morphometry. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 477-490.	2.6	31
305	Altered Brain Activation During a Verbal Working Memory Task in Subjects with Amnesic Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 103-118.	2.6	86
306	Differences in hippocampal volume between major depression and schizophrenia: a comparative neuroimaging study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2010, 260, 127-137.	3.2	53

#	ARTICLE	IF	CITATIONS
307	Midregional Proenkephalin A and N-terminal Protachykinin A are decreased in the cerebrospinal fluid of patients with dementia disorders and acute neuroinflammation. <i>Journal of Neuroimmunology</i> , 2010, 221, 62-67.	2.3	16
308	FDG-PET mapping the brain substrates of visuo-constructive processing in Alzheimer's disease. <i>Journal of Psychiatric Research</i> , 2010, 44, 462-469.	3.1	40
309	Multicentre variability of MRI-based medial temporal lobe volumetry in Alzheimer's disease. <i>Psychiatry Research - Neuroimaging</i> , 2010, 182, 244-250.	1.8	46
310	The relation of regional cerebral perfusion and atrophy in mild cognitive impairment (MCI) and early Alzheimer's dementia. <i>Psychiatry Research - Neuroimaging</i> , 2010, 183, 44-51.	1.8	26
311	Blood-based biomarkers of microvascular pathology in Alzheimer's disease. <i>Experimental Gerontology</i> , 2010, 45, 75-79.	2.8	112
312	Total and phosphorylated tau protein as biological markers of Alzheimer's disease. <i>Experimental Gerontology</i> , 2010, 45, 30-40.	2.8	330
313	Distinct cerebrospinal fluid amyloid $\beta$ peptide signatures in sporadic and PSEN1A431E-associated familial Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2010, 5, 2.	10.8	79
314	Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. <i>Molecular Psychiatry</i> , 2010, 15, 138-145.	7.9	156
315	Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 560-574.	46.4	560
316	Genetic Evidence Implicates the Immune System and Cholesterol Metabolism in the Aetiology of Alzheimer's Disease. <i>PLoS ONE</i> , 2010, 5, e13950.	2.5	347
317	Optimal management of Alzheimer's disease patients: Clinical guidelines and family advice. <i>Neuropsychiatric Disease and Treatment</i> , 2010, 6, 243.	2.2	20
318	Advances and perspectives from genetic research: development of biological markers in Alzheimer's disease. <i>Expert Review of Molecular Diagnostics</i> , 2010, 10, 667-690.	3.1	56
319	Galantamine for Alzheimer's disease. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 345-354.	3.3	69
320	Alzheimer Disease: Functional Abnormalities in the Dorsal Visual Pathway. <i>Radiology</i> , 2010, 254, 219-226.	7.3	44
321	Functional Connectivity Bias of the Orbitofrontal Cortex in Drug-Free Patients with Major Depression. <i>Biological Psychiatry</i> , 2010, 67, 161-167.	1.3	164
322	Functional Representation of Olfactory Impairment in Early Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 581-591.	2.6	66
323	Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. <i>Nature Reviews Neurology</i> , 2010, 6, 131-144.	10.1	1,598
324	Biological markers of amyloid $\beta$ -related mechanisms in Alzheimer's disease. <i>Experimental Neurology</i> , 2010, 223, 334-346.	4.1	145

#	ARTICLE	IF	CITATIONS
325	Age-related networks of regional covariance in MRI gray matter: Reproducible multivariate patterns in healthy aging. <i>NeuroImage</i> , 2010, 49, 1750-1759.	4.2	113
326	Automated detection of brain atrophy patterns based on MRI for the prediction of Alzheimer's disease. <i>NeuroImage</i> , 2010, 50, 162-174.	4.2	287
327	Cognitive intervention in Alzheimer disease. <i>Nature Reviews Neurology</i> , 2010, 6, 508-517.	10.1	149
328	White matter microstructure underlying default mode network connectivity in the human brain. <i>NeuroImage</i> , 2010, 49, 2021-2032.	4.2	185
329	Early and Differential Diagnosis of Dementia and Mild Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 404-417.	1.5	90
330	Validation of Alzheimer's disease CSF and plasma biological markers: The multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). <i>Experimental Gerontology</i> , 2009, 44, 579-585.	2.8	60
331	Regional networks underlying interhemispheric connectivity: An EEG and DTI study in healthy ageing and amnesic mild cognitive impairment. <i>Human Brain Mapping</i> , 2009, 30, 2098-2119.	3.6	85
332	The problem of being a paradigm: the emergence of neural stem cells as example for "Kuhnian" revolution in biology or misconception of the scientific community?. <i>Poiesis &amp; Praxis</i> , 2009, 6, 3-11.	0.3	1
333	Genome-wide association study identifies variants at <i>CLU</i> and <i>PICALM</i> associated with Alzheimer's disease. <i>Nature Genetics</i> , 2009, 41, 1088-1093.	21.4	2,697
334	IFATS Collection: The Conditioned Media of Adipose Stromal Cells Protect Against Hypoxia-Ischemia-Induced Brain Damage in Neonatal Rats. <i>Stem Cells</i> , 2009, 27, 478-488.	3.2	238
335	Assessing neuronal networks: Understanding Alzheimer's disease. <i>Progress in Neurobiology</i> , 2009, 89, 125-133.	5.7	109
336	Blood-Based Microcirculation Markers in Alzheimer's Disease—Diagnostic Value of Midregional Pro-atrial Natriuretic Peptide/C-terminal Endothelin-1 Precursor Fragment Ratio. <i>Biological Psychiatry</i> , 2009, 65, 979-984.	1.3	39
337	Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2009, 69, 8-12.	1.2	61
338	Early risk assessment for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2009, 5, 182-196.	0.8	34
339	CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 385.	7.4	1,009
340	Biological Marker Candidates of Alzheimer's Disease in Blood, Plasma, and Serum. <i>CNS Neuroscience and Therapeutics</i> , 2009, 15, 358-374.	3.9	129
341	Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. <i>Lancet Neurology</i> , The, 2009, 8, 619-627.	10.2	542
342	Decreased Activation Along the Dorsal Visual Pathway After a 3-Month Treatment With Galantamine in Mild Alzheimer Disease. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 147-156.	1.4	35



#	ARTICLE	IF	CITATIONS
343	White Matter Microstructure in Relation to Education in Aging and Alzheimer's Disease1. Journal of Alzheimer's Disease, 2009, 17, 571-583.	2.6	84
344	Anticonvulsants in the treatment of aggression in the demented elderly: an update. Clinical Practice and Epidemiology in Mental Health, 2009, 5, 14.	1.2	14
345	Biological markers for early detection and pharmacological treatment of Alzheimer's disease. Dialogues in Clinical Neuroscience, 2009, 11, 141-157.	3.7	39
346	Lithium Trial in Alzheimer's Disease. Journal of Clinical Psychiatry, 2009, 70, 922-931.	2.2	252
347	19 MRI as a Surrogate Marker in Clinical Trials in Alzheimer's Disease. , 2009, , 305-318.		1
348	Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. Journal of Clinical Psychiatry, 2009, 70, 922-31.	2.2	137
349	Novel MRI techniques in the assessment of dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 58-69.	6.4	79
350	Functional abnormalities of the visual processing system in subjects with mild cognitive impairment: An fMRI study. Psychiatry Research - Neuroimaging, 2008, 163, 248-259.	1.8	52
351	Automated cortical thickness measurements from MRI can accurately separate Alzheimer's patients from normal elderly controls. Neurobiology of Aging, 2008, 29, 23-30.	3.1	242
352	Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study. Neurobiology of Aging, 2008, 29, 812-818.	3.1	94
353	Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimer's and Dementia, 2008, 4, 38-48.	0.8	447
354	The pilot European Alzheimer's Disease Neuroimaging Initiative of the European Alzheimer's Disease Consortium. , 2008, 4, 255-264.		39
355	Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia. International Psychogeriatrics, 2008, 20, 67-76.	1.0	68
356	Increased CSF-BACE 1 activity is associated with ApoE-ε4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. Brain, 2008, 131, 1252-1258.	7.6	109
357	Pharmacological treatment of Alzheimer's dementia: State of the art and current dilemmas. World Journal of Biological Psychiatry, 2008, 9, 69-75.	2.6	13
358	Diagnostic Usefulness of Cognitive Auditory Event-Related P300 Subcomponents in Patients With Alzheimers Disease?. Journal of Clinical Neurophysiology, 2008, 25, 147-152.	1.7	52
359	Fiber Connections between the Cerebral Cortex and the Corpus Callosum in Alzheimer's Disease: A Diffusion Tensor Imaging and Voxel-Based Morphometry Study. Cerebral Cortex, 2007, 17, 2276-2282.	2.9	74
360	No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease. Brain, 2007, 130, e82-e82.	7.6	55

#	ARTICLE	IF	CITATIONS
361	White Matter Damage in Alzheimer Disease and Mild Cognitive Impairment: Assessment with Diffusion-Tensor MR Imaging and Parallel Imaging Techniques. <i>Radiology</i> , 2007, 243, 483-492.	7.3	197
362	Levels of $\beta$ -Secretase (BACE1) in Cerebrospinal Fluid as a Predictor of Risk in Mild Cognitive Impairment. <i>Archives of General Psychiatry</i> , 2007, 64, 718.	12.3	196
363	Morphological substrate of face matching in healthy ageing and mild cognitive impairment: a combined MRI-fMRI study. <i>Brain</i> , 2007, 130, 1745-1758.	7.6	47
364	Tau in cerebrospinal fluid: A sensitive sandwich enzyme-linked immunosorbent assay using tyramide signal amplification. <i>Neuroscience Letters</i> , 2007, 418, 186-189.	2.1	17
365	Multivariate network analysis of fiber tract integrity in Alzheimer's disease. <i>NeuroImage</i> , 2007, 34, 985-995.	4.2	162
366	Multivariate deformation-based analysis of brain atrophy to predict Alzheimer's disease in mild cognitive impairment. <i>NeuroImage</i> , 2007, 38, 13-24.	4.2	185
367	Amyloid $\beta$ peptide ratio 42/40 but not $A\beta_{42}$ correlates with phospho-Tau in patients with low and high CSF $A\beta_{40}$ load. <i>Journal of Neurochemistry</i> , 2007, 101, 1053-1059.	3.9	237
368	Procalcitonin is elevated in the cerebrospinal fluid of patients with dementia and acute neuroinflammation. <i>Journal of Neuroimmunology</i> , 2007, 189, 169-174.	2.3	15
369	Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2007, 257, 330-336.	3.2	28
370	Assessing Therapeutic Efficacy in a Progressive Disease. <i>CNS Drugs</i> , 2006, 20, 311-325.	5.9	57
371	Mild cognitive impairment. <i>Lancet</i> , The, 2006, 367, 1262-1270.	13.7	2,401
372	Caffeic acid phenethyl ester blocks free radical generation and 6-hydroxydopamine-induced neurotoxicity. <i>Life Sciences</i> , 2006, 79, 1307-1311.	4.3	42
373	International quality control survey of neurochemical dementia diagnostics. <i>Neuroscience Letters</i> , 2006, 409, 1-4.	2.1	102
374	Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease. <i>Neurobiology of Aging</i> , 2006, 27, 10-15.	3.1	69
375	Regional network of magnetic resonance imaging gray matter volume in healthy aging. <i>NeuroReport</i> , 2006, 17, 951-956.	1.2	74
376	The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2-BETA1 changes in sporadic Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2006, 96, 635-644.	3.9	123
377	A multicenter reproducibility study of single-voxel 1H-MRS of the medial temporal lobe. <i>European Radiology</i> , 2006, 16, 1096-1103.	4.5	30
378	Neuroanatomy of Down Syndrome in vivo: A Model of Preclinical Alzheimer's Disease. <i>Behavior Genetics</i> , 2006, 36, 405-415.	2.1	131

#	ARTICLE	IF	CITATIONS
379	Comprehensive dissection of the medial temporal lobe in AD: measurement of hippocampus, amygdala, entorhinal, perirhinal and parahippocampal cortices using MRI. <i>Journal of Neurology</i> , 2006, 253, 794-800.	3.6	106
380	Frontal diaschisis in a German case of fatal familial insomnia. <i>Journal of Neurology</i> , 2006, 253, 1510-1512.	3.6	2
381	Effects of donepezil on cortical metabolic response to activation during 18FDG-PET in Alzheimer's disease: a double-blind cross-over trial. <i>Psychopharmacology</i> , 2006, 187, 86-94.	3.1	62
382	Response to Boban et al: computer-assisted 3D reconstruction of the nucleus basalis complex, including the nucleus subputaminalis (Ayala's nucleus). <i>Brain</i> , 2006, 129, E43-E43.	7.6	15
383	Functional connectivity of the fusiform gyrus during a face-matching task in subjects with mild cognitive impairment. <i>Brain</i> , 2006, 129, 1113-1124.	7.6	221
384	CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. <i>Brain</i> , 2006, 129, 3035-3041.	7.6	541
385	Biomarkers in the Diagnosis of Alzheimer's Disease: Are We Ready?. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2006, 19, 172-179.	2.3	52
386	Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. <i>Clinical Chemistry and Laboratory Medicine</i> , 2006, 44, 1472-80.	2.3	145
387	Pattern of interleukin-6 receptor complex immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer's disease brain. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005, 255, 269-278.	3.2	59
388	Identification of Novel Biomarker Candidates by Differential Peptidomics Analysis of Cerebrospinal Fluid in Alzheimers Disease. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2005, 8, 801-806.	1.1	61
389	Focal Decline of Cortical Thickness in Alzheimer's Disease Identified by Computational Neuroanatomy. <i>Cerebral Cortex</i> , 2005, 15, 995-1001.	2.9	390
390	Genetic Association of <i>CDC2</i> with Cerebrospinal Fluid Tau in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 20, 367-374.	1.5	13
391	Correlation of Cerebrospinal Fluid Levels of Tau Protein Phosphorylated at Threonine 231 With Rates of Hippocampal Atrophy in Alzheimer Disease. <i>Archives of Neurology</i> , 2005, 62, 770.	4.5	158
392	Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. <i>Brain</i> , 2005, 128, 2626-2644.	7.6	213
393	Classifying brain states and determining the discriminating activation patterns: Support Vector Machine on functional MRI data. <i>NeuroImage</i> , 2005, 28, 980-995.	4.2	637
394	Increased levels of CSF phosphorylated tau in apolipoprotein E ε4 carriers with mild cognitive impairment. <i>Neuroscience Letters</i> , 2005, 391, 48-50.	2.1	27
395	Reliable manual segmentation of the frontal, parietal, temporal, and occipital lobes on magnetic resonance images of healthy subjects. <i>Brain Research Protocols</i> , 2005, 14, 135-145.	1.6	31
396	Decreased serum amyloid β1-42 autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid β1-42 peptide. <i>Biological Psychiatry</i> , 2005, 57, 813-816.	1.3	70

#	ARTICLE	IF	CITATIONS
397	Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosis of Alzheimer Disease. Archives of General Psychiatry, 2004, 61, 95.	12.3	390
398	Total and Phosphorylated Tau Proteins: Evaluation as Core Biomarker Candidates in Frontotemporal Dementia. Dementia and Geriatric Cognitive Disorders, 2004, 17, 350-354.	1.5	54
399	Age-related cortical grey matter reductions in non-demented Down's syndrome adults determined by MRI with voxel-based morphometry. Brain, 2004, 127, 811-824.	7.6	135
400	Caffeic acid phenethyl ester prevents neonatal hypoxic-ischaemic brain injury. Brain, 2004, 127, 2629-2635.	7.6	99
401	Tumor Necrosis Factor Death Receptor Signaling Cascade Is Required for Amyloid- $\beta$ Protein-Induced Neuron Death. Journal of Neuroscience, 2004, 24, 1760-1771.	3.6	167
402	Value of CSF $\beta$ -amyloid $_{1-42}$ and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Molecular Psychiatry, 2004, 9, 705-710.	7.9	280
403	P2-212 Age-related cortical grey matter reductions in nondemented down's syndrome adults determined by magnetic resonance imaging with voxel-based morphometry. Neurobiology of Aging, 2004, 25, S290.	3.1	2
404	Targets of Antidementia Therapy: Drugs with a Specific Pharmacological Mechanism of Action. Current Pharmaceutical Design, 2004, 10, 223-229.	1.9	6
405	CSF tau and $\beta$ -amyloid as biomarkers for mild cognitive impairment. Dialogues in Clinical Neuroscience, 2004, 6, 379-390.	3.7	27
406	Polymorphisms of the gene encoding the inflammatory cytokine interleukin-6 determine the magnitude of the increase in soluble interleukin-6 receptor levels in Alzheimer's disease. European Archives of Psychiatry and Clinical Neuroscience, 2003, 253, 44-48.	3.2	28
407	Immunotherapy for Alzheimer's disease. Lancet Neurology, The, 2003, 2, 215-220.	10.2	105
408	CSF markers for incipient Alzheimer's disease. Lancet Neurology, The, 2003, 2, 605-613.	10.2	1,156
409	$\beta$ -amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Annals of Neurology, 2003, 54, 263-267.	5.3	82
410	Interleukin $_{-174}$ G/C Promoter Gene Polymorphism C Allele Reduces Alzheimer's Disease Risk. Journal of the American Geriatrics Society, 2003, 51, 578-579.	2.6	53
411	Measurement of $\beta$ - and $\beta$ -secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Experimental Neurology, 2003, 183, 74-80.	4.1	114
412	Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's disease. Neuroscience Letters, 2003, 339, 172-174.	2.1	52
413	The temporal localization of frame-shift ubiquitin-B and amyloid precursor protein, and complement proteins in the brain of non-demented control patients with increasing Alzheimer's disease pathology. Neuroscience Letters, 2003, 348, 46-50.	2.1	17
414	Biological markers for therapeutic trials in Alzheimer's disease. Neurobiology of Aging, 2003, 24, 521-536.	3.1	249

#	ARTICLE	IF	CITATIONS
415	Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and A $\beta$ 42 proteins to phosphorylated tau protein. Brain Research Bulletin, 2003, 61, 243-253.	3.0	75
416	Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A $\beta$ 42 in patients with Alzheimer's disease. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2003, 10, 1-6.	3.0	93
417	Human anti-A $\beta$ -amyloid antibodies block A $\beta$ -amyloid fibril formation and prevent A $\beta$ -amyloid-induced neurotoxicity. Brain, 2003, 126, 1935-1939.	7.6	119
418	Differentiation of Geriatric Major Depression From Alzheimer's Disease With CSF Tau Protein Phosphorylated at Threonine 231. American Journal of Psychiatry, 2003, 160, 376-379.	7.2	83
419	Relation of Corpus Callosum and Hippocampal Size to Age in Nondemented Adults With Down's Syndrome. American Journal of Psychiatry, 2003, 160, 1870-1878.	7.2	96
420	Differential Diagnosis of Alzheimer Disease With Cerebrospinal Fluid Levels of Tau Protein Phosphorylated at Threonine 231. Archives of Neurology, 2002, 59, 1267.	4.5	256
421	Progression of Corpus Callosum Atrophy in Alzheimer Disease. Archives of Neurology, 2002, 59, 243.	4.5	167
422	Age transformation of combined hippocampus and amygdala volume improves diagnostic accuracy in Alzheimer's disease. Journal of the Neurological Sciences, 2002, 194, 15-19.	0.6	47
423	Relation between responses to repetitive transcranial magnetic stimulation and partial sleep deprivation in major depression. Journal of Psychiatric Research, 2002, 36, 131-135.	3.1	22
424	Repetitive Transcranial Magnetic Stimulation (rTMS) in Major Depression Relation between Efficacy and Stimulation Intensity. Neuropsychopharmacology, 2002, 27, 638-45.	5.4	98
425	Human antibodies against amyloid $\beta$ peptide: A potential treatment for Alzheimer's disease. Annals of Neurology, 2002, 52, 253-256.	5.3	152
426	Value of event-related P300 subcomponents in the clinical diagnosis of mild cognitive impairment and Alzheimer's Disease. Psychophysiology, 2002, 39, 175-181.	2.4	109
427	High-resolution peptide mapping of cerebrospinal fluid: a novel concept for diagnosis and research in central nervous system diseases. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 782, 353-361.	2.3	28
428	No association between anti-myelin oligodendrocyte glycoprotein antibodies and serum/cerebrospinal fluid levels of the soluble interleukin-6 receptor complex in multiple sclerosis. Neuroscience Letters, 2001, 305, 13-16.	2.1	10
429	Case Report/Case Series: Severe Hirsutism associated with Psychopharmacological Treatment in Major Depression. World Journal of Biological Psychiatry, 2001, 2, 48-49.	2.6	1
430	Prefrontal Cortex Modulation of Mood and Emotionally Induced Facial Expressions. Journal of Neuropsychiatry and Clinical Neurosciences, 2001, 13, 206-212.	1.8	31
431	Polymorphisms in the apolipoprotein E (APOE) gene in gerontopsychiatric patients. European Archives of Psychiatry and Clinical Neuroscience, 2001, 251, 24-28.	3.2	14
432	Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia, 2001, 35, 72-79.	4.9	358

#	ARTICLE	IF	CITATIONS
433	Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. <i>Annals of Neurology</i> , 2001, 50, 150-156.	5.3	229
434	Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. <i>Annals of Neurology</i> , 2001, 49, 545-546.	5.3	99
435	CSF Total tau, A $\beta$ 42 and Phosphorylated tau Protein as Biomarkers for Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2001, 24, 087-098.	4.0	232
436	Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. <i>Annals of Neurology</i> , 2001, 49, 545-546.	5.3	1
437	Physiology and biochemistry of the interleukin-6 receptor complex: Implications for CNS disorders and Alzheimer's disease. , 2001, , 121-143.		6
438	Translations of Measurements and Scales: Opportunities and Diversities. <i>International Psychogeriatrics</i> , 2000, 12, 391-394.	1.0	11
439	Alzheimer's disease, depression and normal ageing: merit of simple psychomotor and visuospatial tasks. <i>International Journal of Geriatric Psychiatry</i> , 2000, 15, 31-39.	2.7	15
440	Corpus Callosum Measurement as an <i>in Vivo</i> Indicator for Neocortical Neuronal Integrity, but not White Matter Pathology, in Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 2000, 903, 470-476.	3.8	15
441	The neurometabolic landscape of cognitive decline: in vivo studies with positron emission tomography in Alzheimer's disease. <i>International Journal of Psychophysiology</i> , 2000, 37, 87-98.	1.0	56
442	Serotonin transporter (5-HTT) gene polymorphism in psychogeriatric patients. <i>Neuroscience Letters</i> , 2000, 284, 113-115.	2.1	37
443	Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. <i>Neuroscience Letters</i> , 2000, 287, 187-190.	2.1	176
444	Polymorphisms in the $\beta$ -2 macroglobulin gene in psychogeriatric patients. <i>Neuroscience Letters</i> , 2000, 294, 69-72.	2.1	12
445	Inflammation and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2000, 21, 383-421.	3.1	4,069
446	Pisa Syndrome (Pleurothotonus). <i>Journal of Clinical Psychiatry</i> , 2000, 61, 569-574.	2.2	44
447	Oligoclonal Bands and Blood-Cerebrospinal-Fluid Barrier Dysfunction in a Subset of Patients with Alzheimer Disease: Comparison with Vascular Dementia, Major Depression, and Multiple Sclerosis. <i>Alzheimer Disease and Associated Disorders</i> , 1999, 13, 9-19.	1.3	70
448	CSF and serum levels of soluble interleukin-6 receptors (sIL-6R and sgp130), but not of interleukin-6 are altered in multiple sclerosis1Part of this work was presented in abstract form at the Twenty-Seventh Annual Meeting of the Society for Neuroscience, October 25-30, 1997, New Orleans, LA, USA.1. <i>Journal of Neuroimmunology</i> , 1999, 99, 218-223.	2.3	75
449	Discriminant power of combined cerebrospinal fluid IL-6 protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease1Preliminary parts of this study have been presented in abstract form at the 6th International Conference on Alzheimer's Disease and Related Disorders, July 18-23, 1998, Amsterdam, The Netherlands and at the 28th Annual Meeting of the Society for Neuroscience, November 7-12, 1998, Los Angeles, CA, USA.1. <i>Brain Research</i> , 1999, 823, 104-112.	2.2	90
450	Interleukin-6 and the soluble IL-6 receptor are decreased in cerebrospinal fluid of geriatric patients with major depression: no alteration of soluble gp130. <i>Neuroscience Letters</i> , 1999, 259, 145-148.	2.1	56



#	ARTICLE	IF	CITATIONS
451	Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer's disease compared with controls. Neuroscience Letters, 1999, 277, 21-24.	2.1	62
452	Repetitive transcranial magnetic stimulation (rTMS) in pharmacotherapy-refractory major depression: comparative study of fast, slow and sham rTMS. Psychiatry Research, 1999, 88, 163-171.	3.3	274
453	Region-Specific Corpus Callosum Atrophy Correlates With the Regional Pattern of Cortical Glucose Metabolism in Alzheimer Disease. Archives of Neurology, 1999, 56, 467.	4.5	52
454	Aktuelle Möglichkeiten und Perspektiven der Liquoruntersuchung bei der Alzheimer Demenz. , 1999, , 153-166.		0
455	Decreased soluble interleukin-6 receptor in cerebrospinal fluid of patients with Alzheimer's disease. Brain Research, 1998, 780, 356-359.	2.2	52
456	A review of the reversible MAO-A inhibitor moclobemide in geriatric patients. Human Psychopharmacology, 1998, 13, 43-51.	1.5	4
457	Melanoma-Associated Adhesion Molecule MUC18/MCAM (CD146) and Transcriptional Regulator Mader in Normal Human CNS. NeurolImmunoModulation, 1998, 5, 270-276.	1.8	8
458	Corpus Callosum Atrophy Is a Possible Indicator of Region- and Cell Type-Specific Neuronal Degeneration in Alzheimer Disease. Archives of Neurology, 1998, 55, 193.	4.5	178
459	Detection of the Novel CelD Adhesion Molecule MUC18 Human Brain Tissue. NeurolImmunoModulation, 1997, 4, 57-61.	1.8	8
460	Blood-Cerebrospinal Fluid Barrier Dysfunction for High Molecular Weight Proteins in Alzheimer Disease and Major Depression. Alzheimer Disease and Associated Disorders, 1997, 11, 78-87.	1.3	55
461	Frequency Variation of a Pattern-Flash Visual Stimulus during PET Differentially Activates Brain from Striate through Frontal Cortex. NeuroImage, 1997, 5, 116-128.	4.2	70
462	Interleukin-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer's disease. Neuroscience Letters, 1997, 228, 143-146.	2.1	63
463	Fibrin degradation products in post mortem brain tissue of schizophrenics: a possible marker for underlying inflammatory processes. Schizophrenia Research, 1996, 19, 103-109.	2.0	93
464	Psychodrug-induced and EDTA associated thrombocytopenia: important factors in the differential diagnosis of low platelet counts. European Psychiatry, 1996, 11, 416-418.	0.2	1
465	CNS demyelination in monoclonal gammopathy of undetermined significance (MGUS): possible cause of a dementia syndrome. European Psychiatry, 1996, 11, 46-49.	0.2	2
466	Modified Oral Anticoagulant Potency in an Amitriptyline-Treated Patient?. Acta Haematologica, 1996, 96, 178-180.	1.4	3
467	A Case of Ganser's State Presenting as a Dementia Syndrome. Psychopathology, 1996, 29, 236-241.	1.5	15
468	Unstable Anticoagulation in the Course of Amitriptyline Treatment. Pharmacopsychiatry, 1996, 29, 33-37.	3.3	5

#	ARTICLE	IF	CITATIONS
469	Evidence of Blood-Cerebrospinal Fluid-Barrier Impairment in a Subgroup of Patients with Dementia of the Alzheimer Type and Major Depression: A Possible Indicator for Immunoactivation. <i>Dementia and Geriatric Cognitive Disorders</i> , 1995, 6, 348-354.	1.5	24
470	Expression of T Cell [Receptor $\beta$ ] Antigens in Human Brain Tissue. <i>NeuroImmunoModulation</i> , 1995, 2, 115-120.	1.8	18
471	Expression of Human Heat-Shock Protein 70 Antigens and $\alpha$ T-Cell Receptor Antigens in Human Central Nervous Tissue. <i>Annals of the New York Academy of Sciences</i> , 1994, 741, 305-315.	3.8	3